BiotechTube
Artis BioSolutions

Artis BioSolutions

San Diego, United States· Est.
artisbiosolutions.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

Artis BioSolutions is a private, growth equity-backed accelerator focused on the genetic medicine and cell therapy sector. Operating as a services and platform company, it leverages deep operational and scientific expertise to help small-to-mid-size biotechs scale their technologies from Phase 1 to commercial readiness. With leadership experienced in deploying over $250M in GMP facilities and developing over 50 APIs/CRMs, Artis aims to reduce complexity and accelerate timelines for its partners through a combination of capital support, technical know-how, and a scalable approach.

Biologics

Technology Platform

Integrated expertise and services platform for genetic medicine development, specializing in nucleic acids, lipid nanoparticles (LNPs), peptides, enzymes, and analytical development. Supports technology transfer and scaling from Phase 1 to commercial GMP production.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The company is positioned to capitalize on the massive growth and persistent development/manufacturing bottlenecks in the cell & gene therapy and genetic medicine sector.
Its hybrid model of providing both growth capital and deep technical expertise addresses a critical need for small, innovative biotechs, creating a potentially high-value service and investment portfolio.

Risk Factors

Key risks include execution risk in scaling multiple client programs, high dependence on the health of the biotech funding environment, and intense competition from established CDMOs and service providers.
Its success is also tied to the clinical and regulatory success of its partner companies, over which it has limited direct control.

Competitive Landscape

Artis competes in a crowded space that includes large, full-service CDMOs (e.g., Lonza, Catalent), specialized gene therapy CDMOs (e.g., Oxford Biomedica, Andelyn Biosciences), and consulting/operational service firms. Its differentiation lies in combining strategic growth equity investment with hands-on operational and technical expertise, targeting a specific niche of founder-led companies requiring both capital and scaling know-how.

More companies in Cell & Gene Therapy →More companies in United States →